Best Read Articles on COVID-19 Drug-Related News in 2021
The attention-getting articles about COVID-19 included news about Pfizer's booster and the FDA's rejection Zyesami (aviptadil) for treatment of COVID-19-related respiratory failure.
FDA Rejects EUA for COVID-19 Respiratory Failure Therapy
The FDA didn’t have enough data to assess the risks and benefits of Zyesami.
Amber Specialty, Hy-Vee to Dispense Regeneron Monoclonal Antibody for COVID-19
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
Pfizer Submits EUA for COVID-19 Vaccine Booster for All Adults
The FDA had previously issued an EUA for those over the age of 65 and those at high risk for severe COVID-19 or exposure to the virus.
Concerns About Childhood COVID-19 Vaccines Persist, Despite FDA Committee OK
Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
FDA Issues EUA for Pfizer COVID-19 Vaccine for Children
The dose is one-third of the dose given to people 12 years and older.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
